Context.—: Distinguishing between renal oncocytic tumors, such as renal oncocytoma (RO), and a subset of tumors with overlapping characteristics, including the recently identified low-grade oncocytic tumor (LOT), can present a diagnostic challenge for pathologists owing to shared histopathologic features.

Objective.—: To develop an automatic computational classifier for stratifying whole slide images of biopsy and resection specimens into 2 distinct groups: RO and LOT.

Design.—: A total of 269 whole slide images from 125 cases across 6 institutions were collected. A weakly supervised attention-based multiple-instance-learning deep learning (DL) model was trained and initially evaluated through 5-fold cross validation with case-level stratification, followed by validation using an independent holdout data set. Quantitative performance evaluation was based on accuracy and the area under the receiver operating characteristic curve (AUC).

Results.—: The developed model data set yielded generalizable performance, with a 5-fold average testing accuracy of 84% (AUC = 0.78), and a closely aligning accuracy of 83% (AUC = 0.92) on the independent holdout data set.

Conclusions.—: The proposed artificial intelligence approach contributes toward a comprehensive solution for addressing commonly encountered renal oncocytic neoplasms, encompassing well-established entities like RO along with the challenging "gray zone" LOT, thereby proving applicable in clinical practice.

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2024-0374-OADOI Listing

Publication Analysis

Top Keywords

renal oncocytic
12
oncocytic neoplasms
8
renal oncocytoma
8
low-grade oncocytic
8
oncocytic tumor
8
slide images
8
independent holdout
8
holdout data
8
data set
8
renal
6

Similar Publications

A low-grade oncocytic tumor of the kidney (LOT) is a distinctive entity categorized under the 2022 World Health Organization (WHO) classification as "Other oncocytic tumors of the kidney." It represents a unique subset of oncocytic tumors, distinct from oncocytoma and chromophobe renal cell carcinoma. Characterized by bland oncocytic cells that diffusely express CK7 and lack CD117 expression, LOT typically manifests as a solitary, small lesion with a low stage.

View Article and Find Full Text PDF

Background: Low-grade oncocytic tumor (LOT) of the kidney is an emerging entity among renal oncocytic tumors. While the histological features of LOT of the kidney are similar to those of renal oncocytoma, LOT immunohistochemically expresses keratin 7 (KRT7) but not KIT while renal oncocytoma expresses KIT. Molecular analyses of LOTs of the kidney using next generation sequencing revealed those tumors harbor mutations of mTOR-related genes.

View Article and Find Full Text PDF

Oncocytic papillary renal cell carcinoma (OPRCC) is a new papillary renal cell carcinoma (OPRCC) added to the 2016 WHO Classification of Tumors of the Urinary and Male Reproductive System. It is a subtype of carcinoma, PRCC, which is very rare and it is very characteristic and interesting. The morphology, immunophenotype, genetic characteristics and prognosis of OPRCC are uncertain, so the diagnosis and post-operative management of OPRCC are challenging.

View Article and Find Full Text PDF

Context.—: Distinguishing between renal oncocytic tumors, such as renal oncocytoma (RO), and a subset of tumors with overlapping characteristics, including the recently identified low-grade oncocytic tumor (LOT), can present a diagnostic challenge for pathologists owing to shared histopathologic features.

Objective.

View Article and Find Full Text PDF

What Is New in Pathologic Diagnosis and Classification of the Common Renal Cell Neoplasms?

Surg Pathol Clin

March 2025

Department of Pathology and Laboratory Medicine, Cleveland Clinic, 9500 Euclid Avenue L25, Cleveland, OH 44195, USA. Electronic address:

Diagnostic challenges remain among the common renal cell carcinoma (RCC) subtypes. High-grade clear cell RCC may have deceptive patterns, for example BAP1-deficient tumors. Subtyping type 1 and 2 papillary RCC is no longer recommended, as former type 2 tumors may now be contain other diagnostic entities, such as FH-deficient RCC, MITF family RCC, or others.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!